The Valley Desk

ArticleFuture oncology (London, England)Published

Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Sulfonamides; Nitriles; Pyrazoles; Pyrimidines; Pyrrolidines; Protein Kinase Inhibitors; Treatment Outcome; Retrospective Studies; Aged; Aged, 80 and over; Middle Aged
PubMed ID
37991002
PubMed Central ID
PMC11318674
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal